Astrazeneca (AZN) Net Income (2009 - 2026)

Astrazeneca (AZN) has reported Net Income for 18 consecutive years, with $833.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income rose 233.92% year-over-year to $833.0 million; the TTM figure through Mar 2026 stood at $922.0 million (up 212.44% YoY), while the FY2025 annual figure was $10.2 billion, up 45.33% from the prior year.
• Net Income came in at $833.0 million for Q1 2026 at Astrazeneca, up from -$150.0 million in the prior quarter.
• The five-year high for Net Income was $1.5 billion in Q2 2022, with the low at -$935.0 million in Q4 2022.
• Average Net Income over 5 years is $24.7 million, with a median of $148.0 million recorded in 2022.
• Across the five-year window, Net Income plunged 3500.0% in 2022 and surged 675.0% in 2024, its largest moves.
• Year by year, Net Income stood at -$935.0 million in 2022, then advanced by 5.56% to -$883.0 million in 2023, then surged by 118.8% to $166.0 million in 2024, then plunged by 190.36% to -$150.0 million in 2025, then jumped by 655.33% to $833.0 million in 2026.
• According to Business Quant data, Net Income over the past three periods registered $833.0 million, -$150.0 million, and $669.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.